Sarepta Therapeutics Inc. (SRPT)
NASDAQ:SRPT
Want to see SRPT full AI Analyst Report?
SRPT Stock Chart & Stats
$21.55
$1.44(1.16%)
At close: 4:00 PM EST
$21.55
$1.44(1.16%)
Day’s Range― - ―
52-Week Range$10.42 - $43.92
Previous CloseN/A
Volume185.86K
Average Volume (3M)3.06M
Market Cap
$1.72B
Enterprise Value$2.46B
Total Cash (Recent Filing)$653.19M
Total Debt (Recent Filing)$1.04B
Price to Earnings (P/E)26.2
Beta1.16
Next Earnings
Aug 05, 2026EPS Estimate
0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.62
Shares Outstanding105,576,225
10 Day Avg. Volume2,813,559
30 Day Avg. Volume3,056,977
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.98
Price to Sales (P/S)1.03
P/FCF Ratio-7.33
Enterprise Value/Market Cap1.43
Enterprise Value/Revenue1.13
Enterprise Value/Gross Profit1.80
Enterprise Value/Ebitda19.68
Forecast
1Y Price Target
$22.16Price Target Upside2.82% Upside
Rating ConsensusHold
Number of Analyst Covering20
EPS Forecast (FY)3.46
Revenue Forecast (FY)$1.81B
Bulls Say, Bears Say
Bulls Say
High Gross Margins & ProfitabilitySarepta reported 82% unit gross margins and a GAAP operating profit in Q1, indicating structurally high-margin economics typical of specialized therapeutics. Durable gross margins provide operating leverage, help absorb commercial lumpiness, and support sustained R&D and commercialization investment.
Strong Cash Position & Funding AbilityA $748 million cash and investments balance and management’s assertion that they can fund pipeline programs without equity raises materially improves strategic flexibility. This reduces near-term dilution risk, funds clinical readouts and salesforce expansion, and supports multi-year development plans.
Advancing SiRNA Portfolio With Encouraging Early DataPromising Phase 1/2 siRNA readouts (dose-dependent exposure, strong target engagement, muscle delivery) materially de-risk a platform opportunity beyond DMD. Successful siRNA programs can diversify future revenue streams and reduce reliance on a single one-time therapy, supporting longer-term growth.
Bears Say
Alevitus Demand & Information GapManagement cites an information gap and persistent misperceptions that have produced measured Alevitus demand and a gradual recovery path. Because Alevitus is a one-time therapy with long decision cycles, this structural uptake friction can cause sustained revenue variability and higher commercialization costs.
Revenue Distorted By Non-cash Collaboration ItemsQ1 included $325 million of non-cash Roche-related revenue, inflating top-line results versus underlying product sales. Reliance on lumpy, non-cash collaboration items reduces revenue quality and makes it harder to assess durable product momentum and cash generation over multiple quarters.
Inconsistent Cash Generation & FCF ConversionCash generation recently improved to TTM positivity, but free cash flow fell sharply versus the prior period and operating cash is modest relative to revenue. This inconsistent cash conversion, plus planned large payments (e.g., Arrowhead), creates structural funding risk if product sales don’t sustain improvement.
Sarepta Therapeutics News
SRPT FAQ
What was Sarepta Therapeutics Inc.’s price range in the past 12 months?
Sarepta Therapeutics Inc. lowest stock price was $10.41 and its highest was $43.91 in the past 12 months.
What is Sarepta Therapeutics Inc.’s market cap?
Sarepta Therapeutics Inc.’s market cap is $1.72B.
When is Sarepta Therapeutics Inc.’s upcoming earnings report date?
Sarepta Therapeutics Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 62 days.
How were Sarepta Therapeutics Inc.’s earnings last quarter?
Sarepta Therapeutics Inc. released its earnings results on May 06, 2026. The company reported $2.88 earnings per share for the quarter, beating the consensus estimate of $0.976 by $1.904.
Is Sarepta Therapeutics Inc. overvalued?
According to Wall Street analysts Sarepta Therapeutics Inc.’s price is currently Undervalued.
Does Sarepta Therapeutics Inc. pay dividends?
Sarepta Therapeutics Inc. does not currently pay dividends.
What is Sarepta Therapeutics Inc.’s EPS estimate?
Sarepta Therapeutics Inc.’s EPS estimate is 0.21.
How many shares outstanding does Sarepta Therapeutics Inc. have?
Sarepta Therapeutics Inc. has 105,576,225 shares outstanding.
What happened to Sarepta Therapeutics Inc.’s price movement after its last earnings report?
Sarepta Therapeutics Inc. reported an EPS of $2.88 in its last earnings report, beating expectations of $0.976. Following the earnings report the stock price went down -9.683%.
Which hedge fund is a major shareholder of Sarepta Therapeutics Inc.?
Currently, no hedge funds are holding shares in SRPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sarepta Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$22.16 (2.82% Upside)
$22.16 (2.82% Upside)
Blogger Sentiment
Neutral
SRPT Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 4.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $123.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.21%
12-Months-Change
Fundamentals
Return on Equity
4.89%
Trailing 12-Months
Asset Growth
-8.27%
Trailing 12-Months
Company Description
Sarepta Therapeutics Inc.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
SRPT Company Deck
SRPT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a largely constructive tone: Sarepta reported profitable Q1 results, strong gross margins, and a $748M cash balance while reiterating full-year guidance of $1.2B–$1.4B. The company highlighted meaningful clinical progress—notably robust early siRNA data (FSHD, DM1), encouraging EMBARK 3‑year and MRI evidence for Alevitus, regulatory progress with sNDA submissions, and commercialization initiatives (expanded sales force). Offsetting these positives were lower Alevitus product sales driving a modest YoY revenue decline (–2%), an information gap slowing demand recovery, short-term cash outflows tied to planned Arrowhead payments, and unresolved safety/regulatory uncertainty for non‑ambulatory Alevitus use that depends on small open‑label cohorts. Overall, the call emphasized stabilization and long‑term opportunity but signaled that commercial recovery for Alevitus will be gradual and that some clinical/regulatory risks remain.View all SRPT earnings summariesSRPT Stock 12 Month Forecast
Average Price Target
$22.16
▲(2.82% Upside)
Technical Analysis
BioCryst
―
Mesoblast
―
Cogent Biosciences
―
Arcutis Biotherapeutics
―
Dyne Therapeutics
―
Ownership Overview
2.08% Insiders
16.57% Mutual Funds
15.54% Other Institutional Investors
35.53% Public Companies and
Individual Investors